Vir Biotechnology director granted shares, options
Vir Biotechnology director Charles Elliott Sigal reported equity awards and updated holdings.
Rhea-AI Filing Summary
Vir Biotechnology director Charles Elliott Sigal reported equity awards and updated holdings. He received 8,000 restricted stock units under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received stock options for 16,000 shares at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 39,806 shares of common stock directly and 10,000 shares indirectly through Sigal Family Investments, LLC, for which he disclaims beneficial ownership beyond his economic interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 24,000 shares
Grant/Award
3 txns
Insider
Sigal Charles Elliott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 8,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,000 contracts (Direct);
Common Stock — 39,806 shares (Direct);
Common Stock — 10,000 shares (Indirect, By Sigal Family Investments, LLC)
Footnotes (4)
- F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- F2. The RSUs will vest in full on May 27, 2027.
- F3. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F4. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Key Figures
RSU grant: 8,000 units
Stock options granted: 16,000 options
Option exercise price: $9.10 per share
+4 more
7 metrics
RSU grant
8,000 units
Restricted stock units granted May 27, 2026
Stock options granted
16,000 options
Stock Option (Right to Buy) dated May 27, 2026
Option exercise price
$9.10 per share
Conversion or exercise price for 16,000 options
Option vesting date
May 27, 2027
Options vest and become exercisable in full
Option expiration date
May 26, 2036
Expiration for 16,000 stock options
Direct common shares after grant
39,806 shares
Total direct holdings following transactions
Indirect common shares
10,000 shares
Held through Sigal Family Investments, LLC
Key Terms
restricted stock units (RSUs), Equity Incentive Plan, Stock Option (Right to Buy), beneficial ownership
4 terms
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 16,000 underlying common shares."
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Vir Biotechnology (VIR) disclose for Charles Elliott Sigal?
Vir Biotechnology reported equity grants to director Charles Elliott Sigal. He received 8,000 restricted stock units and stock options for 16,000 shares, both dated May 27, 2026, as part of his compensation rather than open-market purchases or sales.
What are the terms of the stock options granted to Charles Elliott Sigal at Vir Biotechnology (VIR)?
Sigal received stock options on 16,000 Vir Biotechnology shares at a $9.10 exercise price. These options vest in full on May 27, 2027 and expire on May 26, 2036, providing a long-dated right to buy common stock.
When do Charles Elliott Sigal’s Vir Biotechnology (VIR) RSUs vest?
The 8,000 restricted stock units granted to Sigal vest in full on May 27, 2027. These RSUs were issued under Vir Biotechnology’s Equity Incentive Plan and convert into common shares upon vesting, assuming continued service through that date.
Are Charles Elliott Sigal’s Vir Biotechnology (VIR) transactions open-market trades?
No, the reported Vir Biotechnology transactions are grants, not open-market trades. The Form 4 shows award-type acquisitions of RSUs and stock options coded as "A", reflecting compensation rather than discretionary buying or selling in the market.
How are Sigal’s indirect Vir Biotechnology (VIR) holdings reported?
Sigal’s Form 4 reports 10,000 Vir Biotechnology shares held indirectly. These shares are owned through Sigal Family Investments, LLC, and he disclaims beneficial ownership of the securities except to the extent of his pecuniary interest in that entity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
